Bristol Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Bristol Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-9,500	Closed	-$231K	–	82
2018 Q2	$231K	Buy	+9,500	New	+$194K	0.45%	42
2017 Q3	–	Sell	-9,500	Closed	-$316K	–	79
2017 Q2	$316K	Hold	9,500	–	–	0.21%	36
2017 Q1	$305K	Buy	+9,500	New	+$324K	0.35%	32

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Bristol Advisors's TEVA Position: Q3 2018 in Review

Bristol Advisors sold out of Teva Pharmaceuticals (TEVA) in Q3 2018, closing a stake of 9,500 shares — an estimated $231K sold.

Bristol Advisors first reported a position in TEVA in Q1 2017 and held it in 3 quarters. The position peaked at $316K in Q2 2017. 556 funds tracked by Wall St. Rank hold TEVA as of Q3 2018.

Bristol Advisors reported no remaining Teva Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Bristol Advisors sold 9,500 Teva Pharmaceuticals shares in Q3 2018, an estimated $231K.
Bristol Advisors first reported a position in Teva Pharmaceuticals in Q1 2017 and held it in 3 quarters.
Bristol Advisors's Teva Pharmaceuticals position peaked at $316K in Q2 2017.
556 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2018.

Based on Bristol Advisors's 13F filing for Q3 2018, filed 17 Oct 2018.